ATAI Sahil Kirpekar sells $66K worth of shares
Mar 25, 2025, 4:31 AM
0.00%
What does ATAI do
ATAI Life Sciences NV, a Berlin-based clinical-stage biopharmaceutical company, focuses on developing treatments for mental health disorders and went public on June 18, 2021. Key compounds include PCN-101 for treatment-resistant depression and DMX-1002 for opioid use disorder.
Sahil Kirpekar sold 48,563 shares of ATAI on 21 March at $1.35 per share, worth a total of $66K. They now own 115,636 ATAI shares, or a 30% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.